#Syre

StockTitan

@stocktitan.net

1 week ago

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 46,600 shares granted to two non-executive employees under the 2018 Plan. The grants were approved March 2, 2026 and comply with Nasdaq Listing Rule 5635(c)(4).The options carry a 10-year term, an exercise price of $42.49 per share (closing price on March 2, 2026), and vest 25% after one year then monthly at 1/48th thereafter, subject to continuous service and plan terms.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

Market Wire News

@marketwirenews.com

3 weeks ago

NEWS: ( NASDAQ: #SYRE ) Expected earnings - Spyre Therapeutics Inc.

Kamratpostaren Öst

@ost.kamratpostaren.se

3 weeks ago

Om två timmar startar Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5! i Stockholm!
#Syre #Samtal

Kamratpostaren

@kamratpostaren.se

3 weeks ago

Om två timmar startar Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5! i Stockholm!
#Syre #Samtal

Kamratpostaren Öst

@ost.kamratpostaren.se

3 weeks ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren

@kamratpostaren.se

3 weeks ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren Öst

@ost.kamratpostaren.se

3 weeks ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren

@kamratpostaren.se

3 weeks ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren Öst

@ost.kamratpostaren.se

1 month ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren

@kamratpostaren.se

1 month ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

StockTitan

@stocktitan.net

1 month ago

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics (NASDAQ: SYRE) announced that its Compensation Committee approved inducement stock options to purchase 108,155 shares for employee Kate Chevlen in connection with her appointment as Chief Commercial Officer.The grant was approved on January 22, 2026, provided under the 2018 Equity Inducement Plan, and was disclosed as material to the employee's acceptance under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $34.09, equal to Spyre's Nasdaq closing price on January 22, 2026. Vesting is 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service and the 2018 Plan terms.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

Kamratpostaren Öst

@ost.kamratpostaren.se

1 month ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

Kamratpostaren

@kamratpostaren.se

1 month ago

Basinkomst, framtiden – och en världsledande forskare. Guy Standing gästar Syres basinkomstöl #5!
När: 20/2 17:00
Var: Stockholm
#Syre #Samtal

StockTitan

@stocktitan.net

2 months ago

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 “6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2 SKYWAY basket trial

#SYRE Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

www.stocktitan.net/news/SYRE/spyre-therapeu...

Silicon Vikings

@siliconvikings.bsky.social

4 months ago

H&M-backed Syre targets $700m raise after Nike deal Swedish textile startup Syre plans to raise up to $700m to build its next factory, after signing a lucrative deal with Nike.

#sthlmtech textile recycling startup #Syre plans to raise up to $700 million to build its next factory, following a lucrative deal with Nike. By @Siftedeu

https://sifted.eu/articles/syre-700m-nike-deal #NordicMade #recyclingtech #textiletech

StockTitan

@stocktitan.net

4 months ago

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock options for 19,600 shares to one non-executive employee under the 2018 Equity Inducement Plan. The grants were approved on November 3, 2025, have a 10-year term, and an exercise price equal to the $23.78 Nasdaq closing price on November 3, 2025. Vesting is one-fourth on the first anniversary of the employee’s start date and then 1/48th monthly thereafter, subject to continuous service. The options were described as material to the employee’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

4 months ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A

#SYRE Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

4 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination therapies for IBD with potential for

#SYRE Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

4 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at ACR Convergence 2025 on Oct 24, 2025 covering interim Phase 1 and preclinical data for SPY072.Key points: six‑month follow‑up from the Phase 1 study shows SPY072 was reported as well tolerated, demonstrated a differentiated pharmacokinetic profile supporting quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 20 weeks at the lowest dose. Preclinical rodent data were presented showing anti‑TL1A treatment met or exceeded etanercept efficacy in a collagen‑induced arthritis model. Posters relate to the ongoing SKYWAY Phase 2 basket study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Posters are available via the ACR program.

#SYRE Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

5 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Spyre Therapeutics (NASDAQ: SYRE) priced an underwritten public offering of 14,864,865 common shares at $18.50 per share, expected to generate approximately $275.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2,229,729 shares at the public offering price.The offering is expected to close on or about October 15, 2025, subject to customary closing conditions. A registration statement (Form S-3, File No. 333-285341) became effective on March 7, 2025.

#SYRE Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

5 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory

#SYRE Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

5 months ago

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics (NASDAQ: SYRE) announced on Oct 3, 2025 that its independent Compensation Committee approved inducement stock option awards to three non-executive employees under the 2018 Equity Inducement Plan.The awards, approved on Oct 1, 2025, total 42,500 options with a 10-year term and an exercise price of $16.46—the Nasdaq closing price on Oct 1, 2025. Options vest 25% on the first anniversary of each employee’s start date and then monthly at 1/48th thereafter, subject to continued service, and remain subject to the terms of the 2018 Plan.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

9 months ago

Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires Biotech firm grants equity inducement awards at $15.40 per share with 4-year vesting schedule. Strategic move strengthens IBD treatment development team. See details.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

10 months ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Spyre Therapeutics (NASDAQ:SYRE) reported Q1 2025 financial results and provided updates on its clinical pipeline. The company has $565 million in cash, providing runway into H2 2028. Key developments include: Pipeline Progress: - SPY001 (α4β7 antibody): Extended Phase 1 data shows good tolerability and potential for quarterly/biannual dosing - SPY002 (TL1A antibodies): Interim Phase 1 data expected this quarter; planned Phase 2 trials in UC and RA - SPY003 (IL-23 antibody): First participant dosed in Phase 1 trial Financial Results: - R&D expenses: $41.6M (Q1 2025) vs $34.9M (Q1 2024) - Net loss: $44.8M (Q1 2025) vs $43.9M (Q1 2024) The company plans to initiate Phase 2 studies mid-2025 in ulcerative colitis and rheumatoid arthritis, targeting markets worth approximately $50B annually, with 7+ proof-of-concept readouts expected in 2026-2027.

#SYRE Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

10 months ago

Breakthrough IBD Drug Shows Triple the Half-Life: Spyre's SPY001 Could Reduce Treatment Frequency from Monthly to Biannual New Phase 1 data reveals SPY001's superior half-life vs vedolizumab, supporting quarterly dosing for IBD patients. Platform Phase 2 trial starting mid-2025. See results.

#SYRE Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

10 months ago

Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires Discover how Spyre Therapeutics strengthens its IBD treatment team with strategic equity grants worth over $944K. See full vesting schedule and compensation details.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

11 months ago

Biotech Spyre Therapeutics Awards 93,200 Stock Options in Key Talent Push New employees receive equity awards with 10-year terms. Options priced at $15.295 with four-year vesting schedule. Details on compensation structure inside.

#SYRE Spyre Therapeutics Announces Grants of Inducement Awards

www.stocktitan.net/news/SYRE/spyre-therapeu...

StockTitan

@stocktitan.net

11 months ago

Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment Novel antibody SPY003 begins human trials with potential for quarterly dosing, marking Spyre's fourth on-time trial launch. Platform expansion planned for 2025.

#SYRE Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

www.stocktitan.net/news/SYRE/spyre-therapeu...